An important abstract presented at the 2019 American Society of Clinical Oncology (ASCO) meeting reported an update of the CheckMate 204 study,[1] a phase 2 trial of ipilimumab 3 mg/kg plus nivolumab 1 mg/kg induction therapy given to patients who had melanoma and previously untreated brain ...
CheckMate204:「YO」联合与黑色素瘤脑转移 超过70% 的 IV 期黑色素瘤患者最终会发展为脑转移,而脑转移正是这些患者疾病加重与死亡的主要原因之一。由于 CheckMate067 临床研究排除了脑转移患者入组,CheckMate204 成为首个评估 YO 联合治疗用于黑色...
Wang et al. performed a phase 3 trial comparing the effectiveness of a novel anti-PD-L1 antibody, adrebrelimab, combined with chemotherapy versus placebo + chemotherapy in extensive-stage SCLC patients, including liver and BrM [126]. It was shown that the median OS was significantly incre...
4170 Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs) Ann. Oncol., 26 (Supplement 9) (2015), pp. ix125-ix147 CrossrefGoogle Scholar [14] L....